EPISODE · Feb 4, 2026 · 15 MIN
686. 三联疗法攻克胰腺癌肿瘤耐药性
from 知为谁 · host 知为谁
这项研究介绍了一种针对胰腺癌的新型三联疗法，旨在攻克该疾病极高的耐药性难题。来自西班牙国家癌症研究中心的研究人员开发出一种联合方案，通过DARAXONRASIB、阿法替尼及SD36三款药物，同时阻断肿瘤生长的三个关键信号节点。在临床前模型中，这种策略不仅诱导了肿瘤的完全消退，还成功实现了超过200天的持续疗效且未见复发。由于该疗法在动物实验中表现出良好的安全性，科学家们认为这为未来的临床试验和提升患者生存率奠定了重要基础。这项成果标志着在应对最具挑战性的恶性肿瘤之一方面取得了显著的科研进展。内容来源：https://www.drugtargetreview.com/news/192714/drug-trio-found-to-block-tumour-resistance-in-pancreatic-cancer/
Embed this episode
Ready to play
686. 三联疗法攻克胰腺癌肿瘤耐药性
0:00
15:21
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 知为谁?
This episode is 15 minutes long.
When was this 知为谁 episode published?
This episode was published on February 4, 2026.
Can I download this 知为谁 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!